Dr. Padron on the SRSF2 Mutation in MDS and CMML

Eric Padron, MD
Published: Monday, Dec 23, 2013

Eric Padron, MD, medical oncologist, Moffitt Cancer Center, discusses the SRSF2 mutation in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

Padron says that the SRSF2 mutation has a high frequency, especially in CMML, and probably happens early in the disease evolution. The mutation has also been proven to have some prognostic relevance but the role of the mutation is still unknown. Although the frequency of the mutation is high, Padron says, the location of the mutation is at a single proline.

An abstract at the 2013 ASH Annual Meeting and Exposition tried to identify the consequence of that mutation on the protein’s exact function, which is to bind RNA and aggregate in nuclear organelles called speckles.

Padron says the preliminary data seems to show that these mutations increase the affinity of RNA binding and augment the nuclear speckle dynamics. Further experiments may show that the mutation increases the activity of SRSF2.

Padron says the goal of this project is to see if the mutation is a target.

Eric Padron, MD, medical oncologist, Moffitt Cancer Center, discusses the SRSF2 mutation in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

Padron says that the SRSF2 mutation has a high frequency, especially in CMML, and probably happens early in the disease evolution. The mutation has also been proven to have some prognostic relevance but the role of the mutation is still unknown. Although the frequency of the mutation is high, Padron says, the location of the mutation is at a single proline.

An abstract at the 2013 ASH Annual Meeting and Exposition tried to identify the consequence of that mutation on the protein’s exact function, which is to bind RNA and aggregate in nuclear organelles called speckles.

Padron says the preliminary data seems to show that these mutations increase the affinity of RNA binding and augment the nuclear speckle dynamics. Further experiments may show that the mutation increases the activity of SRSF2.

Padron says the goal of this project is to see if the mutation is a target.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x